| Literature DB >> 35052575 |
Lady Johanna Forero-Rodríguez1,2, Jonathan Josephs-Spaulding2, Stefano Flor2, Andrés Pinzón1, Christoph Kaleta2.
Abstract
Parkinson's Disease (PD) is a neurodegenerative disease, leading to motor and non-motor complications. Autonomic alterations, including gastrointestinal symptoms, precede motor defects and act as early warning signs. Chronic exposure to dietary, environmental heavy metals impacts the gastrointestinal system and host-associated microbiome, eventually affecting the central nervous system. The correlation between dysbiosis and PD suggests a functional and bidirectional communication between the gut and the brain. The bioaccumulation of metals promotes stress mechanisms by increasing reactive oxygen species, likely altering the bidirectional gut-brain link. To better understand the differing molecular mechanisms underlying PD, integrative modeling approaches are necessary to connect multifactorial perturbations in this heterogeneous disorder. By exploring the effects of gut microbiota modulation on dietary heavy metal exposure in relation to PD onset, the modification of the host-associated microbiome to mitigate neurological stress may be a future treatment option against neurodegeneration through bioremediation. The progressive movement towards a systems toxicology framework for precision medicine can uncover molecular mechanisms underlying PD onset such as metal regulation and microbial community interactions by developing predictive models to better understand PD etiology to identify options for novel treatments and beyond. Several methodologies recently addressed the complexity of this interaction from different perspectives; however, to date, a comprehensive review of these approaches is still lacking. Therefore, our main aim through this manuscript is to fill this gap in the scientific literature by reviewing recently published papers to address the surrounding questions regarding the underlying molecular mechanisms between metals, microbiota, and the gut-brain-axis, as well as the regulation of this system to prevent neurodegeneration.Entities:
Keywords: Parkinson’s disease; ROS; heavy metals; human microbiome; neurotoxicity; systems toxicology
Year: 2021 PMID: 35052575 PMCID: PMC8773335 DOI: 10.3390/antiox11010071
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Bacterial metabolites signaling in the intestine. (A) Secondary bile acids, SCFAs and tryptophan metabolites are microbially derived metabolites. Secondary bile acids activate FXR and TGR5, which stimulate different types of cells. Enterochromaffin cells are stimulated promoting 5-HT release and motility in the colon. Enteroendocrine L-cells promote glucose tolerance through release of the incretin GLP-1. Enteric neurons with TGR5 stimulate or inhibit motility [128,129,130]. Bacterial fermentation of dietary fibers leads to the reduction in luminal pH and production of SCFAs [131]. The bacterial-produced SCFAs activate G-protein-coupled receptors (e.g., GPR41, GPR43 and GPR109) on enteroendocrine cells, enterochromaffin cells, and enteric neurons, leading to the increased production of GLP-1 and 5-HT, thus directing changes in gut motility [132]. With regards to colonocytes, anionic-SCFAs enter the cell through a carrier-mediated transport (similar to MCT1), promoting of mitochondrial fatty acid beta-oxidation and reduction in luminal availability of oxygen through PPARγ activation [131,132]. Finally, the reduction in oxygen availability upregulates the expression of tight junction proteins which are important for the maintenance of the gut barrier [132,133]. (B) Under dysbiosis, there is a limited availability of SCFAs, leading to a decreased amount of available substrate for the colonocytes. This leads to a decreased activation of PPARγ and less oxygen uptake in colonocytes causing dysregulation of cellular growth and differentiation, which can be described as a metabolic switch towards anaerobic glycolysis and lactate production. When the concentration of oxygen increases, decreases in the expression of HIF1 lowers tight junction expression, thus further degenerating the gut barrier [131,132,133,134,135,136]. Furthermore, pathogenic interaction with the impaired cells increases their translocation to the lamina propria, thus promoting oxidative stress events and chronic inflammation [133,134,135,136]. Abbreviations: 5-HT, 5-hydroxytryptamine; FXR, farnesoid X receptor; GI, gastrointestinal; GLP-1, glucagon-like peptide-1; HIF1, hypoxia-inducible factor 1; PPARγ, proliferator-activated receptor gamma; TGR5, Takeda G protein-coupled receptor 5.
Figure 2Neuronal and immunity crosstalk. (A) Under homeostasis, macrophages mature within the intestinal mucosa, where they are utilized to capture invading pathogens, recognize antigens, and clear old apoptotic cells within the area. Macrophages then transfer the captured antigens to the dendritic cells, which are responsible for entering the mesenteric lymph nodes to induce the differentiation of peripheral T regulatory (Treg) cells from naïve T cells[161]. These cells constitutively produce IL-10, which promotes the secondary expansion of regulatory T cells in the mucosa and maintains the homeostasis [161,162]. Butyrate is important in the modulation of intestinal macrophages via the inhibition of histone deacetylases and NF-kB, and thus downregulates proinflammatory responses such as IL-6, IL-12 and NO [163,164]. On the other hand, neuron enteric cells are essential for gastrointestinal motility. The Toll-like receptors (TLRs) expressed by enteric neurons can recognize gut microbe-derived signals and influence the gut motility[165]. These cells promote crosstalk with the Muscularis Macrophages (MMs) in longitudinal and circular smooth muscles and incite the production of the growth factor bone morphogenetic protein 2 (BMP2) to stimulate motility that is directed by the neurons. In turn, the enteric neurons through the production of macrophage survival factor CSF1 promote the maintenance of the MM [152,165,166]. (B) Under dysbiotic conditions, the epithelial barrier is impaired; this in turn leads to the translocation of microbiota, toxins, and deleterious exposures, as suggested by Braak’s Hypothesis, thereby leading to the activation of the host immune response. Macrophages then produce proinflammatory cytokines and present antigens to dendritic cells; together, both cells induce the expansion of TH1 and TH17, thereby recruiting other innate effector cells such as neutrophils and eosinophils [162,163,164]. Additionally, excess TLR activation by the microbiota or toxins, activates cytokine release, proinflammatory responses, and apoptosis in enteric neurons. Thus, MMs decrease the expression of BMP2, and enteric neurons decrease the expression of CSF1 and MM motility[152,166]. Enteric bacteria can further influence the development and differentiation of CD4+and CD8+ T cells, as well as B cell activity and IgA production [167,168]. Abbreviations: BMP2, bone morphogenetic protein 2; CSF1, colony stimulating factor 1; Interferon γ (IFN-γ); TLRs, Toll-like receptors; TNF-α, tumor necrosis factor-alpha.
Figure 3Human exposure to heavy metals in the diet underlies neurodegenerative diseases. Multiple levels of environmental exposure to heavy metals, which are derived from pollution, lead to adverse effects on the gut and brain in humans.
Figure 4Gut–microbiome metal uptake. (A) Mechanisms of microbial heavy metal bioremediation in the gut: 1. Biosorption 2. Bioaccumulation, 3. Biotransformation [216]. (B) Schematic of intestinal metal transport: The primary mechanisms by which iron and other divalent metals (Pb2+, Hg2+, Fe2+, Mn2+) are taken up by the enterocyte is through DMT-1 from the luminal membrane[217]. In the case of Fe3+, this metal is reduced to Fe2+ by DYCTB [217]. Other receptors for Zn2+ (ZIP, ZnT) [201,218,219,220,221,222], Ca2+ and amino acids transporters (b0,+, PepT1) [201,223,224] are utilized to uptake MeHg or other metal ions. Iron was also suggested to be transported with heme with HCP1 and as ferritin [225]. Once entering the intracellular space, metals are readily stored as ferritin (Fe2+) with metallothioneins and exported into the body circulation through ferroportin or other transporters (LAT, ZIP, ZnT) [201,218,219,220,221,222,226,227,228]. Ferritin is converted to Fe3+ by ferroxidase, which is then released for use by transferrin, other metals are transported by albumin or bound to other cell-derived proteins [201,229]. Abbreviations: HCP-1, Heme carrier protein; Znt, Zinc transporter; ZIP, RT, IRT-like protein; LAT, L-type/large neutral amino acid transporter; MRPs, Multidrug Resistance-Related Protein; DMT-1, Divalent metal transporter 1; DYCTB, Duodenal cytochrome B.
Molecular mimicry of metals throughout the gut–brain axis.
| Transporters | Molecule/Ion Metal Being Mimicked | Metal Replacement | Cells Containing the Transporters of the Transporter | Citation |
|---|---|---|---|---|
| Organic anion transporters: | CH3Hg+ | Endothelial cells/Glial cells/Enterocytes | [ | |
| OAT1 | GSH | |||
| Cysteine | GS-Cd-S-G | |||
| OAT3 | ||||
| CH3Hg-S-Cys | ||||
| Zinc-regulated zinc transporter 1 (hZTL1) | Zn 2+ | Cd2+ | Enterocytes/Neurons | [ |
| Ca2+ channels | Ca2+ | Cd2+ | Neurons/Endothelial cells/glial cells | [ |
| Pb2+ | ||||
| Mn2+ | ||||
| Divalent metal transporter 1 | Fe2+ | Pb2+ | Enterocytes/Endothelial cells/Neurons/Glial cells | [ |
| DMT-1 | Mn2+ | |||
| Cd2+ | ||||
| Zinc-imidazolate polymers (ZIPs) | Zn 2+ | Pb2+ | Enterocytes/Endothelial/Astrocytes | [ |
| 1.2 | Mn2+ | |||
| 8, 14 | Cd2+ | |||
| Hg2+ | ||||
| Transferrin receptor | Fe2+ | Mn2+ | Neurons/Endothelial cells/Glial cells | [ |
| TfR | ||||
| Amino acid transporters (system b0,+, system L) | Cysteine | CH3Hg-S-Cys | Enterocytes/Endothelial cells/Glial cells | [ |
| Methionine | Cys-S-Hg-S-Cys | |||
| Cys-S-Cd-S-Cys | ||||
| CH3Hg-S-CysGly | ||||
| Multidrug resistance-associated proteins | CH3Hg+ | Enterocytes/Endothelial cells/glial cells | [ | |
| MRP 1, 2, 3,4 | GSSG | G-S-Cd-S-G | ||
| GSH | CH3Hg-S-G | |||
| As (III) | ||||
| As–GSH | ||||
| Ferroportin | Fe2+ | Cd2+ | Enterocytes/Endothelial cells/Neurons/Oligodendrocytes/Astrocytes | [ |
| Mn2+ | ||||
| Glucose permeases | Glucose | As (III) | Enterocytes/Endothelial cells/Astrocytes | [ |
| GLUT 1, 2, 5 | ||||
| Sodium-dependent phosphate transporters | Phosphate | As(V) | Enterocytes | [ |
| NaPiIIb | ||||
| Aquaporins | Glycerol | As(III) | [ | |
| AQP 3, 10 | Water | Hg2+ | Enterocytes/Enteric neurons/Endothelial cells/Astrocytes | |
| AQP 4 | Pb2+ | |||
| Fe2+ | ||||
| Mn2+ | ||||
| Organic anion transporting polypeptides | Amphipathic organic compounds | As(III) | Enterocytes/Astrocytes/Endothelial | [ |
| OATPB |
Metal ions and ROS/NOS adversely oxidize neuroproteins and lipid metabolism.
| Metal Ion | Reactive Species | Oxidized Molecules | Adverse Outcomes | Cite |
|---|---|---|---|---|
| Lead | Pb2+ | δ-aminolevulinic acid dehydratase (ALAD) | Reduces the antioxidant (glutathione) levels | [ |
| Hydrogen peroxide Superoxide radical | Superoxide dismutase (SOD) | Oxidative stress | ||
| Hydroxyl radicals | Catalase | Alteration in Ca2+ influx | ||
| Glucose-6-phosphate dehydrogenase (G6PD) | Apoptosis | |||
| GSH | ||||
| Glutathione reductase | ||||
| Glutathione peroxidase | ||||
| Glutathione s-transferase | ||||
| Voltage-gated calcium (Ca2+) channels | ||||
| N-methyl-d-aspartate (NMDA) | ||||
| Cadmium | Cd2+ | Thioredoxin | Depresses antioxidants (glutathione) levels | [ |
| Superoxide anion | Cysteine | Oxidative stress | ||
| Hydrogen peroxide | Ubiquitin enzymes | Damage in the electron transport chain | ||
| Hydroxyl radicals | Mitochondrial Complex II III | Apoptosis | ||
| Topoisomerase II | Lipid peroxidation | |||
| DNA methyltransferases | Alteration in maintaining genomic integrity | |||
| GSH | ||||
| Glutathione reductase | ||||
| Glutathione peroxidase | ||||
| Glutathione s-transferase | ||||
| Mercury | MeHg | DNA | Depresses antioxidants (glutathione) levels | [ |
| Hg2+ | Thioredoxin reductase | Oxidative stress | ||
| Hydrogen peroxide | Nitric oxide synthase | Lipid peroxidation | ||
| Nitric oxide | Monoamine oxidase | Mitochondrial function | ||
| Glutathione reductase | Decreases GABA signaling | |||
| Glutathione peroxidase | Neurotransmitter metabolism | |||
| Astrocytic glutamine transporter | Glutamine uptake | |||
| Choline acetyltransferase | Acetylcholine synthesis | |||
| Creatine kinase | Decrease ATP production | |||
| Cytosolic phospholipase A2 | Membrane damage in Endothelial cells | |||
| Enolase | ||||
| Glutamate transporters | ||||
| Ca2+ ATP | ||||
| Mn | Mn2+ | Dopamine | Impairment of oxidative phosphorylation | [ |
| Mn3+ | SOD | Decrease ATP synthesis | ||
| DA-o-quinone | Complex I, II | Disruption of mitochondrial energy production | ||
| Aminochrome | Aconitase | Alteration in Ca2+ influx | ||
| Adenylate cyclase | ||||
| Succinate | ||||
| Malate | ||||
| Glutamate | ||||
| N-methyl-d-aspartate (NMDA) | ||||
| ATP synthase | ||||
| Iron | Fe2+ | Complex I III | Lipid peroxidation | [ |
| Fe3+ | SOD | Dopamine metabolism | ||
| Hydrogen peroxide Superoxide radical | α-synuclein | Mitochondrial functions disruption in ATP synthesis | ||
| Hydroxyl radicals | Tyrosine hydroxylase | Apoptosis | ||
| 3,4- dihydroxyphenylacetaldehyde DA-o-quinone | Hydrogen peroxide | DNA/protein degradation | ||
| 6-hydroxydopamine | Lipid peroxide | |||
| Aminochrome | DNA/RNA | |||
| Creatine kinase BB | ||||
| Cytochrome c oxidase | ||||
| Ketoglutarate dehydrogenase | ||||
| Arsenic | iAsV | ATP synthase | Uncouples oxidative phosphorylation | [ |
| iAsIII | β-tubulin | Decrease ATP formation in the mitochondria | ||
| Monomethyl arsonous acid (MMAIII), | Glucose 6-arsenate | Inhibition of the hexokinase | ||
| Monomethylarsonic acid (MMAV) | Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) | Decrease in mitochondrial biogenesis | ||
| Dimethylarsinous acid (DMAIII), and | Mitochondrial transcription factor A (TFAM) | |||
| Dimethylarsinic acid (DMAV) | Pyruvate dehydrogenase | |||
| Arsenic triglutathione |
Figure 5Heavy metals and oxidative stress in neuronal cells: the disruption of BBB through metal neurotoxicity and molecular mimicry. (A) Mn, Fe and other toxic metals accumulate within the mitochondria by utilizing the MCU. An increase in oxidative stress insults leads to a dysfunction of the mitochondrial electron transport chain. Metals that are able to bind to ADP via ATP-synthase uniquely uncouples oxidative phosphorylation and ATP formation within the mitochondria. Pb2 has an inhibitory effect on the activity of calmodulin and, consequently, leads to the avoidance of synaptic vesicles release [311,312,313,314,319,320,321,322]. (B) In the neuronal synapses, PB, Cd, and Mn impair Ca2+ channels (voltage-gated Ca2+ and Ca2+ ATPase) leading to Ca2+ ion avoidance and alterations in ion signaling. Pb2 has an inhibitory effect on the activity of calmodulin and consequently leads to the avoidance of synaptic vesicle release [323,324]. In the binding sites of postsynaptic cells at the NMDA-receptor/channel, and AMPA disturbances of the postsynaptic potential, leads to the synaptic plasticity and induction of LTP[323,324,325]. (C) Glial cells further increase the production of ROS by mitochondrial damage. Specifically, alterations in antioxidant levels and metal reactions further promote the activation of the NF-kB pathway by the release of proinflammatory cytokines (TNF-α, IL-1, IL-6). Increased cellular damage associated with the accumulation of metals promotes α -synuclein formation in astrocytes leads to the suppression of protective functions and a decrease in glutamate uptake, leading to excitotoxicity in neurons [326,327,328,329,330,331,332,333]. (D) In endothelial cells, the increase in ROS production promotes the release of metalloproteinase-9 and PGE-2 by endothelial cells. This factor then stimulates both pericytes and glial cells to further promote pro-inflammatory signals and, as a consequence, degrades the extracellular matrix of both tight junctions and BBB permeability [41,273,283]. (E) The interaction of glial cells with ROS leads to mitochondrial damage and the release of proinflammatory cytokines, which are further bolstered by the additional burden of heavy metals. This impairs the essential roles of neuron maintenance by disrupting glutamate/GABA-glutamine shuttling. The expression of EAAT1 and EAAT2 and the activity of glutamine synthetase can be downregulated by the excess of intra-astroglial heavy metals [334,335,336,337]. Thus, glutamine catabolism and elevated extracellular glutamate further induces excitotoxicity and neuronal damage, finally leading to neurodegeneration[334,338,339]. Abbreviations: AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, DMT1: Divalent metal transporter 1, DAT: dopamine active transporter, EAAT: excitatory amino acid transporter, IL-1: Interleukin-1, IL-6: In-terleukin-6, IL-12: Interleukin-12, JAM: junctional adhesion molecule, LTP: Long term potentiation, MCU: mitochondrial calcium uniporter, MMP-9/-3: metalloproteinase-9/-3, MRP: Multidrug resistance-associated proteins, MTs: metallothioneins, NMDA: N-Methyl-D-Aspartic acid, NADPH oxidase: nicotinamide adenine dinucleotide phosphate oxidase, NF-κB: nuclear factor kappa, PGE-2: Prostaglandin E2, PECAM: Platelet/endothelial cell adhesion mole-cule-1, ROS: Reactive oxygen species, TfR: Transferrin receptor, TNF: Tumor Necrosis Factor, VE-CADHERINE: vascular endothelial cadherin, ZIP: Zinc-imidazolate polymers, ZnT1: zinc transporter protein-1.
Gut microbial interactions with metals, both antagonistic and synergistic.
| Probiotic Microorganism | Toxic Element | Model/Cell Line | Treatment Effects | Citation |
|---|---|---|---|---|
|
| Arsenic, Cadmium, Mercury, Lead | Humans | Reduction in toxic levels in blood and microbiota changes (Succinivibrionaceae and Gammaproteobacteria families) | [ |
| Mix of microorganisms: | Arsenic, Cadmium, Mercury, Lead | Humans | Concentration of Cd, Hg, and Pb in breast milk, lower concentration of Cd in stools from newborns treated with the probiotics | [ |
|
| Cadmium, Lead | Caco-2 cells | Reduce translocation of toxics | [ |
| Cadmium, Mercury | Rats | Increasing GSH levels, SOD activity and catalase, decrease lipid peroxidation in liver and kidney and decrease ALT, AST and ALP activities, bilirubin, creatinine and urea levels in serum | [ | |
| Arsenic | Rats | Ameliorating the toxic effects on testis and blood metabolites, increase antioxidant enzyme activity (glutathione-s-transferase) | [ | |
| Cadmium | Human hepatoma cell line | Increase cell viability by binding to the toxic metal | [ | |
| Cadmium | Rat hepatocytes, Rats | Decrease genotoxicity through binding to toxic metal | [ | |
| Cadmium | Rats | Increase in toxic metal secretion by feces and decrease in concentration in the blood. Normalized ALT and AST activities | [ | |
|
| Cadmium | Murine RAW 264.7 cells | Inhibits cytotoxicity and intracellular Ca2+ mobilization; suppressed the expression of AP-1 and MAPK protecting against inflammation | [ |
|
| Cadmium | Human intestinal cell line HT-29 and mice | Protection against cell damage, reversed the disruption of tight junctions, protected against inflammation, and decreased the intestinal permeability | [ |
|
| Cadmium | Mice | Protected against genotoxic and spermatotoxic effects | [ |
|
| Cadmium | Rats | Decreased AST, ALT, BUN, bilirubin (increased by toxic exposition) and metal accumulation in the liver and kidney | [ |
| Cadmium | Mice | Increased toxic excretion in feces, and increasing β-catenin and BDNF in brain tissue | [ | |
|
| Cadmium | Mice | Through toxic metal binding, decreased levels of toxic metal in blood and attenuation levels of MDA and GSH | [ |
|
| Cadmium | Mice | Reduced tissue deposition, increased fecal secretion of toxic, and increased enzymatic activity | [ |
|
| Cadmium | Fish | Reduced Cd accumulation in organs, modulate antioxidant activity and intestinal microbial composition | [ |
| Lactobacillus plantarum | Cadmium | HT-29 cells, mice | Inhibition of metal absorption, alleviated cytotoxicity, reversal of the disruption of tight junctions and inhibition of inflammation | [ |
|
| Cadmium | Fish | Mitigation of oxidative stress in tissues and reversed alterations in hematological and biochemical parameters | [ |
|
| Cadmium | Fish | Decreased number of micronucleus formation in erythrocytes and improvement of animal survival rate. | [ |
|
| Cadmium | Mice | Modulation of gut microbiota composition | [ |
|
| Lead | Mice | Decreased toxic levels in blood and tissues, recover blood δ-aminolevulinic acid dehydratase activity, avoidance of alterations in glutathione, glutathione peroxidase, superoxide dismutase, malondialdehyde, and reactive oxygen species | [ |
|
| Lead | Mice | Induced fecal metal excretion through hepatic bile acids synthesis, enhanced biliary glutathione and increased fecal bile acid excretion. | [ |
| Lead | Mice | Increase in the expression of TJ proteins (ZO-1, occludin and claudin-1), increased fecal Pb excretion, increase SCFAs, pH and oxidative reduction in the intestinal lumen | [ | |
|
| Cadmium | Mice | Decrease intestinal metal absorption, tissue accumulation, oxidative stress and ameliorate hepatic histopathological changes | [ |
|
| Lead | Fish | Decreased oxidative stress, reversed alterations in hemato-biochemical parameters, and restored intestinal enzymatic activities | [ |
| Lead | Broiler Chicks | Improved antioxidant parameters, liver transaminases, decreased accumulation of metals and morphological alterations | [ | |
|
| Lead | Mice | Increased fecal excretion, decreased oxidative stress, lipid peroxide by decreasing MDA concentration, and improved antioxidant production | [ |
| Lead | Broiler Chicks | Reduced metal tissue accumulation, decreased lipid peroxidation, and normalized antioxidant activity | [ | |
|
| Mercury | Mice | Reduced intestinal inflammation and decreased oxidative stress | [ |
| and | Mercury | Rats | Decreased tissue accumulation of toxic metal, avoided antioxidant alterations, normalized creatinine, bilirubin, urea AST, and ALT levels | [ |
| Mercury | Rats | Protection against the adverse effects in the brain and kidney. Increased activity of glutathione-S-transferase, lactate dehydrogenase, normalized creatinine, triglycerides levels and modulate histopathological changes in the brain. | [ |
Interactions of probiotic microbiota and their effects on the gut–brain axis.
| Probiotic Microorganism | Model | Outcome | Citation |
|---|---|---|---|
|
| Humans | Improves stool consistency and bowel habits | [ |
| Humans | Decreases The Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), biomarkers of inflammation and oxidative stress (high-sensitivity C-reactive protein (hs-CRP), Malondialdehyde (MDA), Glutathione) and insulin metabolism. | [ | |
| Humans | Downregulates gene expression levels of IL-1, IL-8 and TNF-α; increases the gene expression of TGF-β and PPAR-γ | [ | |
| Humans | Improves abdominal pain, bloating and constipation with incomplete evacuation | [ | |
| Humans | Improves constipation in PD patients | [ | |
| Lactobacillus salivarius LS01 and | Peripheral blood mononuclear cells from PD patients and Caco-2 cells | Reduces proinflammatory cytokines, oxidative stress and increased the anti-inflammatory response and protection of the epithelium from gut permeability | [ |
| Mice | Increases levels of BDNF, GDNF and dopamine, and decreases levels of MAO-B in the brain. | [ | |
| Mice | Preserves dopamine neurons, reduces the motor impairments, and maintains tyrosine hydroxylase in neurons | [ |